The effect of zidovudine on neuropsychiatric measures in HIV-infected men.
The authors examined the effects of zidovudine on neuropsychiatric measures, at three assessment points separated by 6 months, in 25 HIV-positive men who took zidovudine for at least 6 months and a comparison group of 25 HIV-positive men with similar CD4+ T cell counts who had never taken zidovudine. Zidovudine had no statistically significant effect except for a slight improvement in Global Assessment of Functioning scale score. In this small group of subjects there was little benefit but also little evidence of CNS toxicity from zidovudine.
Gorman
J M
JM
HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, NY 10032.
Mayeux
R
R
Stern
Y
Y
Williams
J B
JB
Rabkin
J
J
Goetz
R R
RR
Ehrhardt
A A
AA
D015496:CD4-Positive T-Lymphocytes; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D009483:Neuropsychological Tests; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use*
D015215:Zidovudine